NEW YORK, April 7, 2021 /PRNewswire/ — atai Life Sciences (“atai” or the “Company”), a global biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, has acquired a majority stake in Delaware based Psyber, a company dedicated to developing interventions to improve various mental health disorders and induce behavioural changes through…


Previous articleMusic is a ‘Hidden Therapist’ in Psilocybin Therapy
Next articlePsychedelic Research Bulletin: March 2021